文献速递慢阻肺

GOLD A组和B组患者伴或不伴急性加重史的未来加重风险与死亡率

Exacerbation Risk and Mortality in Global Initiative for Chronic Obstructive Lung Disease Group A and B Patients with and without Exacerbation History.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

这项瑞典全国队列研究纳入45,350例慢阻肺患者,按GOLD A0、A1、B0、B1和E分组随访。结果显示,过去一年有过一次中度急性加重的A1和B1患者,未来急性加重和住院风险显著高于无加重史的A0和B0,但死亡率无显著差异,提示新ABE分类中加重史对风险分层有重要价值。

要点

  • B1组未来急性加重风险显著高于B0组(HR 2.56,95%CI 2.40-2.74)。
  • B1组全因住院和呼吸住院风险高于B0组,但死亡率无显著差异。
  • A1与A0的比较结果与B1和B0类似,支持将加重史纳入A、B组分层。

核心结论

  • 在GOLD A组和B组患者中,区分过去一年有无一次急性加重史可提供有价值的未来风险信息,应影响预防性治疗推荐。

研究设计与样本

  • 全国性队列研究,纳入2017年1月至2020年8月在瑞典国家气道登记处注册、年龄≥30岁的慢阻肺患者,共45,350例,随访至2021年1月。

主要发现

  • 纳入患者中25%为A0、4%为A1、44%为B0、10%为B1、17%为E。
  • 中度急性加重、全因和呼吸住院、全因和呼吸死亡率随GOLD组A0-A1-B0-B1-E递增,但中度急性加重在A1中高于B0。
  • B1组相比B0组未来急性加重HR为2.56(95%CI 2.40-2.74),全因住院HR为1.28(95%CI 1.21-1.35),呼吸住院HR为1.44(95%CI 1.27-1.62)。
  • B1组相比B0组全因死亡HR为1.04(95%CI 0.91-1.18),呼吸死亡HR为1.13(95%CI 0.79-1.64)。
  • B1组急性加重率为0.6次/患者年,B0组为0.2次/患者年(率比2.55,95%CI 2.36-2.76)。

临床怎么用

  • 对GOLD A组和B组患者,应询问并记录过去一年急性加重史,以识别A1和B1等高未来风险人群。
  • B1患者未来急性加重和住院风险显著高于B0,可能需要更积极的预防性治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Risk stratification of patients according to chronic obstructive pulmonary disease severity is clinically important and forms the basis of therapeutic recommendations. No studies have examined the association for Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A and group B patients with (A1 and B1, respectively) and without (A0 and B0, respectively) an exacerbation in the past year with future exacerbations, hospitalizations, and mortality in perspective with the new GOLD ABE classification. Objectives: The aim was to examine the association between GOLD A0, A1, B0, B1, and E patients and future exacerbations, respiratory and cardiovascular hospitalizations, and mortality. Methods: In this nationwide cohort study, we identified patients with a diagnosis of chronic obstructive pulmonary disease, aged ⩾30 years, and registered in the Swedish National Airway Register between January 2017 and August 2020. Patients were stratified in GOLD groups A0, A1, B0, B1, and E and were followed until January 2021 for exacerbations, hospitalizations, and mortality in national registries. Measurements and Main Results: The 45,350 eligible patients included 25% A0, 4% A1, 44% B0, 10% B1, and 17% E. Moderate exacerbations, all-cause and respiratory hospitalizations, and all-cause and respiratory mortality increased by GOLD group A0-A1-B0-B1-E, except for moderate exacerbations, which were higher in A1 than in B0. Group B1 had a substantially higher hazard ratio for future exacerbation (2.56; 95% confidence interval [95% CI] 2.40-2.74), all-cause hospitalization (1.28; 1.21-1.35), and respiratory hospitalization (1.44; 1.27-1.62), but not all-cause (1.04; 0.91-1.18) or respiratory (1.13; 0.79-1.64) mortality than group B0. The exacerbation rate for group B1 was 0.6 events per patient-year versus 0.2 for group B0 (rate ratio, 2.55; 95% CI, 2.36-2.76). Results were similar for group A1 versus group A0. Conclusions: Stratification of GOLD A and B patients with one or no exacerbation in the past year provides valuable information on future risk, which should influence treatment recommendations for preventive strategies.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Vanfleteren, Lindberg, Zhou, et al. Exacerbation Risk and Mortality in Global Initiative for Chronic Obstructive Lung Disease Group A and B Patients with and without Exacerbation History. Am J Respir Crit Care Med. 2023. PMID: 37040482. doi:10.1164/rccm.202209-1774OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。